Neurology Alert – January 1, 2018

January 1, 2018

• How Helpful Is Bevacizumab in Recurrent Glioblastoma?

  In a randomized Phase III trial, the addition of bevacizumab to lomustine did not improve overall survival in patients with recurrent glioblastoma compared to lomustine alone.

  Read more

• The Incidence of Dementia May Be Declining

  In community-dwelling people from Bronx County, New York, there was a sharp decrease in dementia incidence in those born after mid-1929, which could not be readily explained by changes in the prevalence of cardiovascular diseases, higher education, or increased racial/ethnic diversity.

  Read more

• Blockade of CGRP for Migraine Prevention: Promising, but Not a Cure

  Blockade of calcitonin gene-related peptide in patients with chronic or episodic migraine results in the prevention of about two headache days a month compared to placebo.

  Read more

• TBI in Prodromal Parkinson’s Disease

  This population-based study using Medicare data demonstrated that in the five years prior to diagnosis of Parkinson’s disease (PD), when compared with age-matched controls, those who were diagnosed with PD had a higher incidence of traumatic brain injury (TBI). The TBI was rated as mild and concussive and was most often related to falls.

  Read more

• Isolated Amyloid Myopathy

  Isolated amyloid myopathy is a rare disorder that can be distinguished from systemic amyloidosis with myopathy by clinical, biochemical, and muscle biopsy histologic criteria.

  Read more

• Thrombectomy Is Effective Up to 24 Hours After Stroke – the DAWN Trial

  Among a group of ischemic stroke patients last known to be well six to 24 hours earlier and who had a mismatch between clinical deficit and infarct size, outcomes regarding disability and functional independence were better if treated with mechanical thrombectomy, rather than standard care alone.

  Read more